Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study M. Turgut, P. Moreau, M. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. Spicka, M. Risse, G. Asset, S. Macé, T. Martin

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA (IKEMA): FINAL OVERALL SURVIVAL ANALYSIS Ecenur Guder Arslan, Kwee Yong, Thomas Martın, Meletios Dımopoulos, Joseph Mıkhael, Marcelo Capra, Thierry Facon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martınez, Chang-Ki Mın, Philippe Moreau

UPDATED PROGRESSION-FREE SURVIVAL AND DEPTH OF RESPONSE IN IKEMA, A RANDOMIZED PHASE 3 TRIAL OF ISATUXIMAB, CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA M Capra, P Moreau, M Dimopoulos, J Mikhael, K Yong, T Facon, R Hajek, I Spicka, F Casca, S Macé, M Risse, T Martin